Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Holbrook

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Elife|March 3, 2020
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosisHeledd H Jarosz-Griffiths, Thomas Scambler, Chi H Wong, et al.
The Lancet. Neurology|December 13, 2025
Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trialJulia C Greenland, Kerry Dresser, Emma Cutting, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Elife|March 3, 2020
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosisHeledd H Jarosz-Griffiths, Thomas Scambler, Chi H Wong, et al.
The Lancet. Neurology|December 13, 2025
Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trialJulia C Greenland, Kerry Dresser, Emma Cutting, et al.
Pageof 2